FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3000064468> ?p ?o ?g. }

• W3000064468 endingPage "53" @default.
• W3000064468 startingPage "42" @default.
• W3000064468 abstract "Rationale & ObjectivePeritoneal dialysis (PD)-related peritonitis carries high morbidity for PD patients. Understanding the characteristics and risk factors for peritonitis can guide regional development of prevention strategies. We describe peritonitis rates and the associations of selected facility practices with peritonitis risk among countries participating in the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS).Study DesignObservational prospective cohort study.Setting & Participants7,051 adult PD patients in 209 facilities across 7 countries (Australia, New Zealand, Canada, Japan, Thailand, United Kingdom, United States).ExposuresFacility characteristics (census count, facility age, nurse to patient ratio) and selected facility practices (use of automated PD, use of icodextrin or biocompatible PD solutions, antibiotic prophylaxis strategies, duration of PD training).OutcomesPeritonitis rate (by country, overall and variation across facilities), microbiology patterns.Analytical ApproachPoisson rate estimation, proportional rate models adjusted for selected patient case-mix variables.Results2,272 peritonitis episodes were identified in 7,051 patients (crude rate, 0.28 episodes/patient-year). Facility peritonitis rates were variable within each country and exceeded 0.50/patient-year in 10% of facilities. Overall peritonitis rates, in episodes per patient-year, were 0.40 (95% CI, 0.36-0.46) in Thailand, 0.38 (95% CI, 0.32-0.46) in the United Kingdom, 0.35 (95% CI, 0.30-0.40) in Australia/New Zealand, 0.29 (95% CI, 0.26-0.32) in Canada, 0.27 (95% CI, 0.25-0.30) in Japan, and 0.26 (95% CI, 0.24-0.27) in the United States. The microbiology of peritonitis was similar across countries, except in Thailand, where Gram-negative infections and culture-negative peritonitis were more common. Facility size was positively associated with risk for peritonitis in Japan (rate ratio [RR] per 10 patients, 1.07; 95% CI, 1.04-1.09). Lower peritonitis risk was observed in facilities that had higher automated PD use (RR per 10 percentage points greater, 0.95; 95% CI, 0.91-1.00), facilities that used antibiotics at catheter insertion (RR, 0.83; 95% CI, 0.69-0.99), and facilities with PD training duration of 6 or more (vs <6) days (RR, 0.81; 95% CI, 0.68-0.96). Lower peritonitis risk was seen in facilities that used topical exit-site mupirocin or aminoglycoside ointment, but this association did not achieve conventional levels of statistical significance (RR, 0.79; 95% CI, 0.62-1.01).LimitationsSampling variation, selection bias (rate estimates), and residual confounding (associations).ConclusionsImportant international differences exist in the risk for peritonitis that may result from varied and potentially modifiable treatment practices. These findings may inform future guidelines in potentially setting lower maximally acceptable peritonitis rates. Peritoneal dialysis (PD)-related peritonitis carries high morbidity for PD patients. Understanding the characteristics and risk factors for peritonitis can guide regional development of prevention strategies. We describe peritonitis rates and the associations of selected facility practices with peritonitis risk among countries participating in the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). Observational prospective cohort study. 7,051 adult PD patients in 209 facilities across 7 countries (Australia, New Zealand, Canada, Japan, Thailand, United Kingdom, United States). Facility characteristics (census count, facility age, nurse to patient ratio) and selected facility practices (use of automated PD, use of icodextrin or biocompatible PD solutions, antibiotic prophylaxis strategies, duration of PD training). Peritonitis rate (by country, overall and variation across facilities), microbiology patterns. Poisson rate estimation, proportional rate models adjusted for selected patient case-mix variables. 2,272 peritonitis episodes were identified in 7,051 patients (crude rate, 0.28 episodes/patient-year). Facility peritonitis rates were variable within each country and exceeded 0.50/patient-year in 10% of facilities. Overall peritonitis rates, in episodes per patient-year, were 0.40 (95% CI, 0.36-0.46) in Thailand, 0.38 (95% CI, 0.32-0.46) in the United Kingdom, 0.35 (95% CI, 0.30-0.40) in Australia/New Zealand, 0.29 (95% CI, 0.26-0.32) in Canada, 0.27 (95% CI, 0.25-0.30) in Japan, and 0.26 (95% CI, 0.24-0.27) in the United States. The microbiology of peritonitis was similar across countries, except in Thailand, where Gram-negative infections and culture-negative peritonitis were more common. Facility size was positively associated with risk for peritonitis in Japan (rate ratio [RR] per 10 patients, 1.07; 95% CI, 1.04-1.09). Lower peritonitis risk was observed in facilities that had higher automated PD use (RR per 10 percentage points greater, 0.95; 95% CI, 0.91-1.00), facilities that used antibiotics at catheter insertion (RR, 0.83; 95% CI, 0.69-0.99), and facilities with PD training duration of 6 or more (vs <6) days (RR, 0.81; 95% CI, 0.68-0.96). Lower peritonitis risk was seen in facilities that used topical exit-site mupirocin or aminoglycoside ointment, but this association did not achieve conventional levels of statistical significance (RR, 0.79; 95% CI, 0.62-1.01). Sampling variation, selection bias (rate estimates), and residual confounding (associations). Important international differences exist in the risk for peritonitis that may result from varied and potentially modifiable treatment practices. These findings may inform future guidelines in potentially setting lower maximally acceptable peritonitis rates." @default.
• W3000064468 created "2020-01-23" @default.
• W3000064468 creator A5001352734 @default.
• W3000064468 creator A5002399875 @default.
• W3000064468 creator A5017593148 @default.
• W3000064468 creator A5021770844 @default.
• W3000064468 creator A5022806283 @default.
• W3000064468 creator A5032840007 @default.
• W3000064468 creator A5033857644 @default.
• W3000064468 creator A5042820244 @default.
• W3000064468 creator A5043091888 @default.
• W3000064468 creator A5043394711 @default.
• W3000064468 creator A5054233331 @default.
• W3000064468 creator A5057956524 @default.
• W3000064468 creator A5067719448 @default.
• W3000064468 creator A5073823762 @default.
• W3000064468 creator A5078786005 @default.
• W3000064468 creator A5083226860 @default.
• W3000064468 date "2020-07-01" @default.
• W3000064468 modified "2023-10-18" @default.
• W3000064468 title "Peritoneal Dialysis–Related Infection Rates and Outcomes: Results From the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS)" @default.
• W3000064468 cites W1952975795 @default.
• W3000064468 cites W1984595214 @default.
• W3000064468 cites W1985535517 @default.
• W3000064468 cites W1988571204 @default.
• W3000064468 cites W2008224538 @default.
• W3000064468 cites W2011956000 @default.
• W3000064468 cites W2012053212 @default.
• W3000064468 cites W2017013593 @default.
• W3000064468 cites W2051269014 @default.
• W3000064468 cites W2068237609 @default.
• W3000064468 cites W2083535974 @default.
• W3000064468 cites W2086250091 @default.
• W3000064468 cites W2098248278 @default.
• W3000064468 cites W2098994939 @default.
• W3000064468 cites W2112303766 @default.
• W3000064468 cites W2117591335 @default.
• W3000064468 cites W2119296146 @default.
• W3000064468 cites W2125839304 @default.
• W3000064468 cites W2129834434 @default.
• W3000064468 cites W2131888045 @default.
• W3000064468 cites W2133480008 @default.
• W3000064468 cites W2135794213 @default.
• W3000064468 cites W2141469682 @default.
• W3000064468 cites W2142033731 @default.
• W3000064468 cites W2147435924 @default.
• W3000064468 cites W2149778282 @default.
• W3000064468 cites W2152198134 @default.
• W3000064468 cites W2154275339 @default.
• W3000064468 cites W2164204772 @default.
• W3000064468 cites W2165914204 @default.
• W3000064468 cites W2167969296 @default.
• W3000064468 cites W2169915264 @default.
• W3000064468 cites W2181395530 @default.
• W3000064468 cites W2305592447 @default.
• W3000064468 cites W2305989136 @default.
• W3000064468 cites W2342019090 @default.
• W3000064468 cites W2406351639 @default.
• W3000064468 cites W2418930000 @default.
• W3000064468 cites W2774793441 @default.
• W3000064468 cites W2776083114 @default.
• W3000064468 cites W2778120208 @default.
• W3000064468 cites W2905748278 @default.
• W3000064468 cites W2910244540 @default.
• W3000064468 cites W2918092070 @default.
• W3000064468 cites W2927981269 @default.
• W3000064468 cites W4241142722 @default.
• W3000064468 doi "https://doi.org/10.1053/j.ajkd.2019.09.016" @default.
• W3000064468 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31932094" @default.
• W3000064468 hasPublicationYear "2020" @default.
• W3000064468 type Work @default.
• W3000064468 sameAs 3000064468 @default.
• W3000064468 citedByCount "98" @default.
• W3000064468 countsByYear W30000644682020 @default.
• W3000064468 countsByYear W30000644682021 @default.
• W3000064468 countsByYear W30000644682022 @default.
• W3000064468 countsByYear W30000644682023 @default.
• W3000064468 crossrefType "journal-article" @default.
• W3000064468 hasAuthorship W3000064468A5001352734 @default.
• W3000064468 hasAuthorship W3000064468A5002399875 @default.
• W3000064468 hasAuthorship W3000064468A5017593148 @default.
• W3000064468 hasAuthorship W3000064468A5021770844 @default.
• W3000064468 hasAuthorship W3000064468A5022806283 @default.
• W3000064468 hasAuthorship W3000064468A5032840007 @default.
• W3000064468 hasAuthorship W3000064468A5033857644 @default.
• W3000064468 hasAuthorship W3000064468A5042820244 @default.
• W3000064468 hasAuthorship W3000064468A5043091888 @default.
• W3000064468 hasAuthorship W3000064468A5043394711 @default.
• W3000064468 hasAuthorship W3000064468A5054233331 @default.
• W3000064468 hasAuthorship W3000064468A5057956524 @default.
• W3000064468 hasAuthorship W3000064468A5067719448 @default.
• W3000064468 hasAuthorship W3000064468A5073823762 @default.
• W3000064468 hasAuthorship W3000064468A5078786005 @default.
• W3000064468 hasAuthorship W3000064468A5083226860 @default.
• W3000064468 hasBestOaLocation W30000644681 @default.
• W3000064468 hasConcept C126322002 @default.
• W3000064468 hasConcept C141071460 @default.
• W3000064468 hasConcept C177713679 @default.

• next